Newsfeeds Archive - Spark Newswire

3 minute read

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet

April 19, 12:28 PM

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.

BTC

3 minute read

ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 AACR Annual Meeting

By Benzinga Newsdesk

April 8, 8:15 AM

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2

ORIC

2 minute read

Analyst Ratings

Where ORIC Pharmaceuticals Stands With Analysts

By Benzinga Insights

December 13, 1:00 PM

Over the past 3 months, 4 analysts have published their opinion on ORIC Pharmaceuticals (NASDAQ:ORIC) stock. These analysts…

ORIC

4 minute read

Initial Phase 1 Dose Escalation Data For ORIC-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development At The 65th American Society Of Hematology Annual Meetin…

By Benzinga Newsdesk

December 11, 1:05 PM

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose

ORIC

1 minute read

ORIC Pharmaceuticals To Present Initial Phase 1b Clinical Data For ORIC-533 In Multiple Myeloma At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

November 2, 9:12 AM

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation on the initial Phase

ORIC

2 minute read

Meta To Rally Over 42%? Here Are 10 Top Analyst Forecasts For Thursday

By Lisa Levin

October 26, 7:53 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

ADBE